Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Q3 2021 revenue of $15.1 million and Adjusted EBITDA of $6.9 million, up 15% and 53%, respectively, from Q3 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021. The Company will hold a conference call that...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in two...
Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...
Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...